ROIVANT SCIENCES LTD. Diluted Shares Outstanding (Weighted Average)
ROIVANT SCIENCES LTD. (ROIV) reported Diluted Shares Outstanding (Weighted Average) of 720.78 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 720.78M shares, a 5.95% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 717.30M shares, a 1.37% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 696.86M shares, a 3.58% decline year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 680.95M shares, a 7.41% decline year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for fiscal 2026 was 693.86M shares, a 4.35% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for fiscal 2025 was 725.40M shares, a 12.71% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for fiscal 2024 was 831.05M shares, a 16.59% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, diluted for fiscal 2023 was 712.79M shares, a 6.43% increase from fiscal 2022.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 720.78M shares 10-Q · filed 2026-08-06 | 719.04M shares derived: average of 2 quarters · filed 2026-08-06 | 711.65M shares derived: average of 3 quarters · filed 2026-08-06 | 703.97M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 717.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 707.08M shares derived: average of 2 quarters · filed 2026-05-20 | 698.37M shares derived: average of 3 quarters · filed 2026-05-20 | 693.86M shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 696.86M shares 10-Q · filed 2026-02-06 | 688.90M shares derived: average of 2 quarters · filed 2026-02-06 | 686.05M shares 10-Q · filed 2026-02-06 | 691.43M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | 680.95M shares 10-Q · filed 2025-11-10 | 680.62M shares 10-Q · filed 2025-11-10 | 689.62M shares derived: average of 3 quarters · filed 2026-08-06 | 697.89M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 680.29M shares 10-Q · filed 2026-08-06 | 693.96M shares derived: average of 2 quarters · filed 2026-08-06 | 703.54M shares derived: average of 3 quarters · filed 2026-08-06 | 711.53M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 707.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 715.17M shares derived: average of 2 quarters · filed 2026-05-20 | 721.94M shares derived: average of 3 quarters · filed 2026-05-20 | 725.40M shares 10-K · filed 2026-05-20 |
| 2024-12-31 | 722.72M shares 10-Q · filed 2026-02-06 | 729.09M shares derived: average of 2 quarters · filed 2026-02-06 | 731.32M shares 10-Q · filed 2026-02-06 | 772.77M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | 735.47M shares 10-Q · filed 2025-11-10 | 735.64M shares 10-Q · filed 2025-11-10 | 789.46M shares derived: average of 3 quarters · filed 2026-05-20 | 803.21M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | 781.63M shares 10-Q · filed 2025-08-11 | 816.45M shares derived: average of 2 quarters · filed 2026-05-20 | 825.79M shares derived: average of 3 quarters · filed 2026-05-20 | 811.90M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | 851.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 847.86M shares derived: average of 2 quarters · filed 2026-05-20 | 821.99M shares derived: average of 3 quarters · filed 2026-05-20 | 831.05M shares 10-K · filed 2026-05-20 |
| 2023-12-31 | 844.46M shares 10-Q · filed 2025-02-10 | 807.34M shares derived: average of 2 quarters · filed 2025-02-10 | 824.31M shares 10-Q · filed 2025-02-10 | 778.99M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | 770.23M shares 10-Q · filed 2024-11-12 | 764.78M shares 10-Q · filed 2024-11-12 | 757.17M shares derived: average of 3 quarters · filed 2025-05-29 | 746.21M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | 759.27M shares 10-Q · filed 2024-08-09 | 750.64M shares derived: average of 2 quarters · filed 2025-05-29 | 738.20M shares derived: average of 3 quarters · filed 2025-05-29 | 728.62M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | 742.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | 727.66M shares derived: average of 2 quarters · filed 2025-05-29 | 718.40M shares derived: average of 3 quarters · filed 2025-05-29 | 712.79M shares 10-K · filed 2025-05-29 |
| 2022-12-31 | 713.32M shares 10-Q · filed 2024-02-13 | 706.60M shares derived: average of 2 quarters · filed 2024-02-13 | 703.05M shares 10-Q · filed 2024-02-13 | 700.32M shares derived: average of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | 699.89M shares 10-Q · filed 2023-11-13 | 697.89M shares 10-Q · filed 2023-11-13 | 695.99M shares derived: average of 3 quarters · filed 2023-11-13 | 693.64M shares derived: average of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | 695.88M shares 10-Q · filed 2023-08-14 | 694.04M shares derived: average of 2 quarters · filed 2023-08-14 | 691.56M shares derived: average of 3 quarters · filed 2023-08-14 | 681.23M shares derived: average of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | 692.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | 689.40M shares derived: average of 2 quarters · filed 2023-06-28 | 676.34M shares derived: average of 3 quarters · filed 2023-06-28 | 669.75M shares 10-K · filed 2023-06-28 |
| 2021-12-31 | 686.59M shares 10-Q · filed 2023-02-13 | 668.41M shares derived: average of 2 quarters · filed 2023-02-13 | 662.27M shares 10-Q · filed 2023-02-13 | |
| 2021-09-30 | 650.23M shares 10-Q · filed 2022-11-14 | 650.04M shares 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | 649.86M shares 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |